LAUSR

infections in those treated with prophylactic FQ or b-lactam antibiotics when compared with FT. More evidence continues to accumulate that FT prophylaxis can potentially reduce cost, morbidity and mortality associated with TRUSPB infectious complications. These are pertinent to contemporary practice in the face of a recent Federal Drug Administration warning of disabling and potentially permanent serious side-effects of FQs. Use of FT broadly or as part of targeted antimicrobial prophylaxis regimes with rectal swabs might improve outcomes while more accurate biomarkers and imaging are developed or until wider adoption of transperineal approaches. Larger-scale trials, including more diverse geographical cohorts, are required to further wider adoption, with the greatest benefits most likely to be seen in populations with higher FQ resistance rates.